Buccal delivery of drug provides an alternative to the oral route of drug administration for the drugs that undergo first pass metabolism. This work was concerned with the formulation and in-vitro evaluation of eletriptan hydrobromide mucoadhesive buccal tablets. Eletriptan is used in the treatment of migraine. The objective of this study was to improve the bioavailability of the drug with reduction in dosing frequency and side effects. The tablets were prepared by direct compression method. Nine formulations were developed with varying concentrations of polymers like chitosan, sodium alginate and HPMC. FTIR studies showed no evidence on interaction with drug, polymers and excipients. The tablets were tested for weight variation, hardness, surface pH, drug content uniformity, swelling index, mucoadhesion strength and in-vitro drug release study. The in-vitro drug release profile showed that formulation (F8) which contains polymers such as chitosan and sodium alginate exhibited sustained drug release for 8 hours. The in-vitro release kinetics reveals that the formulation (F8) follows zero order and the mechanism of drug release was non-fickian.
Loading....